E-MTAB-3387 - Gene expression analysis of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type

Submitted on 15 July 2010, last updated on 9 March 2015, released on 15 September 2015
Homo sapiens
Samples (2)
Array (1)
Protocols (5)
Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the changes in the gene expression profile, that accompany resistance development, we treated the erlotinib sensitive non-small cell lung cancer cell line H358 with increasing concentrations of erlotinib (1-5µM) for several weeks (H358res). In parallel, we kept H358 with the same concentrations of the vehicle DMSO (H358co). After ten weeks of treatment, when the H358res stably grew under 5µM erlotinib, total RNA of both cell lines was harvested and hybridized.
Experiment types
transcription profiling by array, stimulus or stress design
ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. Simone Meidhof, Simone Brabletz, Waltraut Lehmann, Bogdan‐Tiberius Preca, Kerstin Mock, Manuel Ruh, Julia Schüler, Maria Berthold, Anika Weber, Ulrike Burk, Michael Lübbert, Martin Puhr, Zoran Culig, Ulrich Wellner, Tobias Keck, Peter Bronsert, Simon Küsters, Ulrich T Hopt, Marc P Stemmler, Thomas Brabletz. EMBO Mol Med 7(6):831-847 (2015), PMID:25872941
Investigation descriptionE-MTAB-3387.idf.txt
Sample and data relationshipE-MTAB-3387.sdrf.txt
Raw data (1)E-MTAB-3387.raw.1.zip
Array designA-GEOD-4454.adf.txt